Heartbeam Inc Surges 53.94% Amid Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 Dec 25
Source: Coinmarketcap
Heartbeam Inc's stock surged by 53.94%, crossing above the 20-day SMA, despite a slight decline in the Nasdaq-100 and S&P 500 indices.
This significant price movement comes as the broader market experiences weakness, with the Nasdaq-100 down 0.17% and the S&P 500 down 0.07%. Investors are reacting positively to Heartbeam's recent developments, which have not been detailed in the news.
The implications of this surge suggest that Heartbeam Inc may be gaining traction among investors, potentially indicating a shift in market sentiment towards the company, even as the overall market struggles.
Analyst Views on BEAT
Wall Street analysts forecast BEAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAT is 5.83 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.640
Low
4.00
Averages
5.83
High
8.00
Current: 1.640
Low
4.00
Averages
5.83
High
8.00
About BEAT
HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
